Kidney Fibrosis Treatment Global Market Report 2025
상품코드:1760585
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신장 섬유증 치료 시장 규모는 향후 수 년간 급성장할 전망입니다. 예측 기간 동안의 성장은 만성 신장 질환의 유병률 증가, 신장 섬유증 관리를 위한 첨단 치료법에 대한 수요 증가, 초기 신장 섬유증 발견에 대한 인식 증가, 신장 질환 치료에서 개인 맞춤형 의학의 채택 증가, 그리고 당뇨병 및 고혈압 발생률 증가와 같은 요인에 의해 주도될 것으로 예상됩니다. 예측 기간에 있어서의 주요 동향으로서는 조기 발견 진단 툴의 진보, 유전자 치료의 진보, 원격 의료나 원격 모니터링에 있어서의 기술의 통합, 줄기 세포 치료의 진보, 약물전달 시스템의 혁신 등을 들 수 있습니다.
만성 신장 질환(CKD)의 유병률 증가는 앞으로 수년간 신장 섬유증 치료 시장의 성장을 이끌 것으로 예측됩니다. 질병으로 인한 신체의 노폐물 축적으로 이어집니다. 신장의 혈관을 손상시키고 노폐물을 여과하는 기능을 손상시키는 당뇨병 증가율은 CKD 증가에 기여하는 중요한 요인입니다. 신장 섬유증 치료는 신장 조직의 흉터를 표적으로 하고, 염증을 억제하고, 신장 장애의 진행을 지연시키고, 결국 신장 기능을 유지하는데 도움이 됩니다. 2024년 5월 미국 질병통제예방센터(CDC)는 미국 성인의 약 14%, 약 3,550만 명이 만성 신장병을 앓고 있다고 보고했습니다.
또한 임상시험 증가도 신장 섬유증 치료 시장의 성장을 뒷받침할 것으로 예상되고 있습니다. 안전성과 효능을 보장하기 위해 광범위한 검사가 필요한 개인 맞춤형 혁신 치료법에 대한 수요가 증가함에 따라 임상 시험이 증가하고 있습니다. 신장 섬유증 치료는 신규의 항섬유화 요법을 중점적으로 시험하는 영역을 제공함으로써 이러한 시험에서 중요한 역할을 하고 있으며 연구자는 신장의 손상을 늦추거나 회복시키는 신약의 효능을 평가할 수 있습니다.
2023년 11월 영국 제약 산업 협회(Association of the British Pharmaceutical Industry)는 영국의 임상 시험 연간 참여자 수가 15% 증가했으며, 2021-22년 3만 6,722명에서 2022-23년에는 4만 2,088명으로 증가했다고 보고했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계신장 섬유증 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 신장 섬유증 치료 시장 : 성장률 분석
세계 신장 섬유증 치료 시장 실적 : 규모와 성장, 2019-2024
세계 신장 섬유증 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 신장 섬유증 치료 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 신장 섬유증 치료 시장 치료유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
안지오텐신 전환효소(ACE) 억제제
안지오텐신 II 수용체 길항제(ARB)
필페니돈
레닌 억제제
혈관 펩티다아제 억제제
기타 치료의 유형
세계의 신장 섬유증 치료 시장 : 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
혈액검사
소변 검사
화상 검사
신생검
세계의 신장 섬유증 치료 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
만성 신장병
신장암의 치료
기타 용도
세계의 신장 섬유증 치료 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
클리닉
연구센터
병원
세계의 신장 섬유증 치료 시장 : 안지오텐신 전환 효소(ACE) 억제제 치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
에나라프릴
캡토프리
리시노프릴
라미프릴
세계의 신장 섬유증 치료 시장 : 안지오텐신 II 수용체 길항제(ARB) 치료 유형별 서브세그먼테이션, 분석과 예측, 2019-2024, 2024-2029F, 2034F
로사르탄
테르미사르탄
발사르탄
일베사르탄
세계의 신장 섬유증 치료 시장 : 피르페니돈 치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
브랜드명 필페니돈
제네릭 필페니돈
세계의 신장 섬유증 치료 시장 : 레닌 억제제 치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
알리스키렌
실험적 레닌 억제제
세계 신장 섬유증 치료 시장 혈관 펩티다아제 억제제 치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
오마파트리랏
산파트리랏
세계 신장 섬유증 치료 시장 : 기타 치료 유형 세분화, 치료 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
항염증제
줄기세포요법
임상시험 중의 항섬유화제
유전자 치료
제7장 지역별/국가별 분석
세계 신장 섬유증 치료 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계 신장 섬유증 치료 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
신장 섬유증 치료 시장 : 경쟁 구도
신장 섬유증 치료 시장 : 기업 프로파일
F. Hoffman-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Cara Therapeutics Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Gilead Sciences Inc.
Novo Nordisk A/S
Boehringer Ingelheim International GmbH
Vertex Pharmaceuticals Incorporated
Chinook Therapeutics Inc.
Reata Pharmaceuticals Inc.
Akebia Therapeutics Inc.
Travere Therapeutics Inc.
Insilico Medicine Inc.
Tvardi Therapeutics Inc.
ProKidney LLC
Alentis Therapeutics AG
La Jolla Pharmaceutical Company
Galecto Biotech AB
Purespring Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
신장 섬유증 치료 시장(2029년) : 새로운 기회를 제공하는 국가
신장 섬유증 치료 시장(2029년) : 새로운 기회를 제공하는 부문
신장 섬유증 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Kidney fibrosis treatment refers to therapeutic approaches aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive buildup of extracellular matrix proteins, such as collagen, leading to scarring and a decline in kidney function, commonly associated with chronic kidney disease (CKD).
The primary treatment types for kidney fibrosis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. ACE inhibitors help lower blood pressure and reduce heart strain by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis involves blood and urine tests, imaging scans, and kidney biopsies. These treatments are used for chronic kidney diseases, kidney cancer, and other related conditions. They are applied by various end-users, such as clinics, research centers, and hospitals.
The kidney fibrosis treatment market research report is one of a series of new reports from The Business Research Company that provides kidney fibrosis treatment market statistics, including the kidney fibrosis treatment industry's global market size, regional shares, competitors with the kidney fibrosis treatment market share, detailed kidney fibrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment market. This kidney fibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The kidney fibrosis treatment market size has grown strongly in recent years. It will grow from $6.93 billion in 2024 to $7.58 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historical period can be attributed to factors such as growing research and development investments in fibrosis-targeting therapies, increasing government funding for kidney disease management initiatives, rising patient awareness of kidney transplantation and fibrosis treatment options, the expansion of healthcare infrastructure, and the growing prevalence of aging populations.
The kidney fibrosis treatment market size is expected to see rapid growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The projected growth in the forecast period is driven by factors including the increasing prevalence of chronic kidney diseases, rising demand for advanced therapies for renal fibrosis management, growing awareness of early-stage kidney fibrosis detection, the rising adoption of personalized medicine in kidney disease treatment, and the increasing incidence of diabetes and hypertension. Key trends in the forecast period include advancements in early detection and diagnostic tools, progress in gene therapy, the integration of technology in telemedicine and remote monitoring, advancements in stem cell therapies, and innovations in drug delivery systems.
The growing prevalence of chronic kidney disease (CKD) is expected to drive the growth of the kidney fibrosis treatment market in the coming years. CKD is a progressive loss of kidney function, often caused by conditions such as diabetes or hypertension, which lead to the accumulation of waste products in the body. The increasing rates of diabetes, which damages kidney blood vessels and impairs their ability to filter waste, are a key factor contributing to the rise in CKD. Kidney fibrosis treatments target kidney tissue scarring, reduce inflammation, and slow the progression of kidney damage, ultimately helping to preserve kidney function. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that around 14% of U.S. adults, or approximately 35.5 million people, are living with chronic kidney disease. As a result, the growing prevalence of CKD is driving the expansion of the kidney fibrosis treatment market.
The increasing number of clinical trials is also expected to fuel the growth of the kidney fibrosis treatment market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and potential side effects of medical treatments or interventions. The rising demand for personalized and innovative therapies, which require extensive testing to ensure safety and efficacy, is driving the increase in clinical trials. Kidney fibrosis treatments play a crucial role in these trials by offering a focused area for testing novel anti-fibrotic therapies, enabling researchers to evaluate the effectiveness of new drugs in slowing or even reversing kidney damage. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported a 15% increase in annual recruitment to clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. As clinical trials continue to grow, so too does the demand for kidney fibrosis treatments.
In May 2023, Chinook Therapeutics, a U.S.-based biotechnology company, partnered with Ionis Pharmaceuticals, another U.S.-based biotech firm, to develop a precision therapy for chronic kidney disease. This collaboration aims to create an antisense oligonucleotide therapy targeting the genetic causes of rare, severe forms of CKD, with the goal of improving patient outcomes and reducing the need for dialysis or kidney transplants. Ionis Pharmaceuticals is also developing therapies for kidney fibrosis, including IONIS-FB-LRx, a treatment for IgA nephropathy, further highlighting the push toward innovative treatments for CKD.
Major players in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.
North America was the largest region in the kidney fibrosis treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the kidney fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Kidney Fibrosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on kidney fibrosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for kidney fibrosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney fibrosis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors; Angiotensin Ii Receptor Blockers (Arbs); Pirfenidone; Renin Inhibitors; Vasopeptidase Inhibitors; Other Treatment Types
3. Kidney Fibrosis Treatment Market Trends And Strategies
4. Kidney Fibrosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Kidney Fibrosis Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Kidney Fibrosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Kidney Fibrosis Treatment Market Growth Rate Analysis
5.4. Global Kidney Fibrosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Kidney Fibrosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Kidney Fibrosis Treatment Total Addressable Market (TAM)
6. Kidney Fibrosis Treatment Market Segmentation
6.1. Global Kidney Fibrosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (Ace) Inhibitors
Angiotensin Ii Receptor Blockers (Arbs)
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors
Other Treatment Types
6.2. Global Kidney Fibrosis Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Urine Tests
Imaging Tests
Kidney Biopsy
6.3. Global Kidney Fibrosis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Kidney Diseases
Kidney Cancer Treatment
Other Applications
6.4. Global Kidney Fibrosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinics
Research Center
Hospitals
6.5. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (Ace) Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enalapril
Captopri
Lisinopril
Ramipril
6.6. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Angiotensin Ii Receptor Blockers (Arbs), By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Losartan
Telmisartan
Valsartan
Irbesartan
6.7. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Pirfenidone, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded Pirfenidone
Generic Pirfenidone
6.8. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Renin Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aliskiren
Experimental Renin Inhibitors
6.9. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Vasopeptidase Inhibitors, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omapatrilat
Sampatrilat
6.10. Global Kidney Fibrosis Treatment Market, Sub-Segmentation Of Other Treatment Types, By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Inflammatory Agents
Stem Cell Therapy
Antifibrotic Agents Under Clinical Trials
Gene Therapy
7. Kidney Fibrosis Treatment Market Regional And Country Analysis
7.1. Global Kidney Fibrosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Kidney Fibrosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
